Endomimetics, a University of Alabama at Birmingham (UAB) start-up, this week announced a $2.8 million funding award from the Small Business Innovation Research (SBIR) program to develop a peptide-based biomaterial for use after medical procedures.
The Endomimetics team will use the grant to perform more research into how effective the biomaterial, called Bionanomatrix, is in improving performance of flow diverters used in treating brain aneurysms.
Bionanomatrix is a coating for medical devices that mimics human tissue and can possibly reduce complications associated with medical device implantation and lessen the need for additional surgeries or procedures.
“Brain aneurysms carry the devastating risk of rupture, leading to death or permanent disability,” said Endomimetics CEO Joseph Garner, Ph.D. “If this research is successful, we plan to partner the technology with a flow diverter manufacturer and begin (FDA) studies and clinical development.”
This application of Bionanomatrix is one of several in development. The technology is to be licensed through the UAB Bill L. Harbert Institute for Innovation and Entrepreneurship.
The federal SBIR program provides support for U.S. small businesses for innovative research and development.
For more information, visit the Endomimetics website.
-- Sept. 27, 2024